Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial

Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial

Abstract Background Sodium-dependent glucose transporter 2 inhibitor (SGLT2i) has the advantages of effectively lowering blood glucose levels and improving renal outcomes in diabetic patients. This study evaluated the effect of canagliflozin on intrarenal lipid content and oxygenation in newly diagn...

Full description

Bibliographic Details
Main Authors: Li Zhang, Tongdan Wang, Yan Kong, Haizhen Sun, Yuling Zhang, Junmei Wang, Zhida Wang, Shan Lu, Pei Yu, Saijun Zhou
Format: Article
Language:English
Published: BMC 2023-12-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Canagliflozin
Type 2 diabetes
Intrarenal lipid content
Renal oxygenation level
Hypoxia
Online Access:https://doi.org/10.1186/s13098-023-01236-1

Internet

https://doi.org/10.1186/s13098-023-01236-1

Similar Items